Results 261 to 270 of about 337,841 (333)
Abstract The aim of this study was to evaluate the bioequivalence and safety of a single application of crisaborole ointment to test formulation and reference formulation in healthy subjects under fasting conditions. A total of 32 subjects were included and divided into 2 groups (test‐reference; reference‐test).
Yanchao Wang+9 more
wiley +1 more source
Short-Coupled Premature Ventricular Contractions in a Young Male with Sudden Cardiac Arrest. [PDF]
Mansoor T+6 more
europepmc +1 more source
Abstract Berzosertib is a small‐molecule ataxia telangiectasia and Rad3‐related protein inhibitor. To assess the clearance mechanism(s) of berzosertib, a Phase 1, 2‐period, open‐label study was conducted in adults with advanced solid tumors who were treated with a single intravenous dose of 210 mg/m2 berzosertib containing approximately 3 µCi of [14C ...
Jayaprakasam Bolleddula+12 more
wiley +1 more source
Common on “craniorachischisis in a stillbirth associated with maternal smoking”
Fenglin Jiang
doaj
Abstract A modified controlled‐release sodium valproate formulation (VAL001, test) was compared with an approved enteric‐coated tablet formulation (Absenor, reference). Pharmacokinetics and safety/tolerability were evaluated in healthy subjects to bridge with positive efficacy results from an early‐phase patient trial of valproate in combination with ...
Nikhil Ahuja+8 more
wiley +1 more source
Abstract A fixed‐dose combination (FDC) tablet formulation of donepezil/memantine (10/20 mg) was developed to improve medication compliance in patients with Alzheimer's disease (AD). This study compared the pharmacokinetic (PK) characteristics and safety profiles of an FDC formulation (donepezil/memantine [10/20 mg]) and single components (SCs) of ...
Minkyu Choi+7 more
wiley +1 more source
Pacing Pandemonium: The Unexpected Outcome of Temporary Pacing. [PDF]
Mondal S, Kakarla S, Namboodiri N.
europepmc +1 more source
Abstract A pediatric‐friendly powder for oral suspension (PfOS) of tovorafenib, a type II RAF inhibitor, was developed for patients with difficulty swallowing tablets. This open‐label, randomized, phase 1 study (QSC205140) evaluated the taste/palatability of PfOS formulations (n = 12), the relative bioavailability of the PfOS versus tablet formulation,
Yang Zhang+6 more
wiley +1 more source